Vigil Neuroscience IncNASDAQ:VIGL
- LAST PRICE3.2100
- TODAY'S CHANGE (%)0.2100 (7.0000%)
- Bid / Lots3.1600/ 7
- Ask / Lots3.2100/ 7
- Open / Previous Close2.9800 / 3.0000
- Day Range
- 52 Week Range
- Volume14,190
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIGL |
|---|---|---|
| 09:32 ET | 830 | 2.98 |
| 10:00 ET | 130 | 3 |
| 10:09 ET | 200 | 3.03 |
| 10:11 ET | 500 | 3.05 |
| 10:24 ET | 100 | 3.0497 |
| 10:40 ET | 400 | 3.09 |
| 10:45 ET | 260 | 3.12 |
| 10:54 ET | 100 | 3.075 |
| 11:12 ET | 200 | 3.095 |
| 11:18 ET | 100 | 3.09 |
| 11:25 ET | 200 | 3.07 |
| 11:36 ET | 100 | 3.11 |
| 11:50 ET | 100 | 3.09 |
| 12:08 ET | 468 | 3.11 |
| 12:12 ET | 400 | 3.12 |
| 12:24 ET | 100 | 3.17 |
| 12:46 ET | 300 | 3.16 |
| 01:02 ET | 300 | 3.18 |
| 01:13 ET | 100 | 3.16 |
| 01:26 ET | 1382 | 3.185 |
| 01:29 ET | 1725 | 3.2358 |
| 01:42 ET | 300 | 3.25 |
| 01:45 ET | 200 | 3.24 |
| 02:00 ET | 300 | 3.22 |
| 02:03 ET | 634 | 3.22 |
| 02:12 ET | 100 | 3.22 |
| 02:34 ET | 100 | 3.22 |
| 02:36 ET | 500 | 3.23 |
| 02:39 ET | 200 | 3.23 |
| 02:43 ET | 400 | 3.21 |
Nov 12, 2024
Vigil Neuroscience to Present at Upcoming Investor Conferences, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Vigil Neuroscience Is Maintained at Outperform by Wedbush, from 10:33AM ET on Friday Nov 08, 2024 by Dow Jones
10:33AM ET on Friday Nov 08, 2024 by Dow JonesDJ Vigil Neuroscience Price Target Maintained With a $17.00/Share by HC Wainwright & Co., from 7:47AM ET on Friday Nov 08, 2024 by Dow Jones
7:47AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Press Release: Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow JonesVigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vigil Neuroscience Inc | 122.6M | -1.6x | --- |
Ventyx Biosciences Inc | 122.3M | -0.8x | --- |
Outlook Therapeutics Inc | 121.4M | -0.6x | --- |
Pyxis Oncology Inc | 124.9M | -1.8x | --- |
Skye Bioscience Inc | 126.5M | -5.0x | --- |
Invizyne Technologies Inc | 117.8M | -23.8x | --- |
Company Information
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Contact Information
- Headquarters
- 100 Forge Road, Suite 700WATERTOWN, MA, United States 02472
- Phone
- 857-254-4445
- Fax
- ---
Executives
- Independent Chairman of the Board
- Bruce Booth
- President, Chief Executive Officer, Director
- Ivana Magovcevic-Liebisch
- Chief Financial Officer
- Jennifer Ziolkowski
- Chief Scientific Officer
- David Gray
- General Counsel
- Christopher Verni
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $122.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.07 |
Book Value | $3.24 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
